# Newleos Therapeutics

> Newleos Therapeutics is a Boston-based, clinical-stage biotechnology company building a new generation of treatments for neuropsychiatric disorders. Launched in February 2025 with an oversubscribed $93.5 million Series A, the company in-licensed four clinical-ready oral small molecules from Roche - targeting GABAA-y1, V1a, TAAR1, and GABAA-a5 - aimed at generalized anxiety, social anxiety, substance use disorders, and cognitive impairment. Its name nods to 'eos,' the Greek word for dawn: a new dawn for mental health treatment.

- **Founded:** 2025
- **Headquarters:** Boston, Massachusetts, United States
- **Founders:** David Donabedian (Co-founder, Founding President & CEO (now advisor)), William Martin (Co-founder, Chief Development Officer), Federico Bolognani (Co-founder, Chief Medical Officer), Christoph Westphal (Co-founder (Longwood Fund)), Miguel Sobral (Co-founder), Rob Hadfield (Co-founder)
- **Team size:** ~27 employees
- **Products:** NTX-1955, NTX-1472 (RO6953958), NTX-2001 (ralmitaront), NTX-1511 (basmisanil)
- **Notable:** Closed an oversubscribed $93.5M Series A at launch in February 2025, Assembled a four-asset clinical-stage pipeline in-licensed from Roche, Attracted top-tier investors including Goldman Sachs Alternatives and Novo Holdings

## Products & services

- **NTX-1955** — Lead program. A GABAA-y1 selective positive allosteric modulator designed to modulate GABAergic transmission in the amygdala (the brain's anxiety circuit), aiming to reduce anxiety while sparing other networks tied to safety liabilities. Targeted at generalized anxiety disorder.
- **NTX-1472 (RO6953958)** — A V1a receptor antagonist in development for social anxiety disorder.
- **NTX-2001 (ralmitaront)** — A TAAR1 partial agonist targeting substance use disorder cravings.
- **NTX-1511 (basmisanil)** — A GABAA-a5 modulator aimed at cognitive impairment in rare neurodevelopmental conditions (e.g., dup15q syndrome).

## Achievements

- Closed an oversubscribed $93.5M Series A at launch in February 2025
- Assembled a four-asset clinical-stage pipeline in-licensed from Roche
- Attracted top-tier investors including Goldman Sachs Alternatives and Novo Holdings
- Recruited Timothy Noyes (two prior biotech IPOs) as President & CEO in October 2025
- Stood up a clinical advisory board to support key neuropsychiatry programs

## Latest updates

- **2025-02** — Debuted publicly with an oversubscribed $93.5M Series A to advance neuropsychiatric medicines.
- **2025-04** — Expanded leadership team and announced a clinical advisory board for key neuropsychiatry programs.
- **2025-10** — Appointed Timothy Noyes as President & CEO, succeeding founding CEO David Donabedian, who moved to an advisory role.

## Links

- Website: https://newleos.com
- LinkedIn: https://www.linkedin.com/company/newleos-therapeutics
- Twitter/X: https://x.com/NewleosTx

---

Profile page: https://yespress.io/newleos-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-13